NAMPT and Miyoshi myopathy: Using metastatic melanoma (MM) as disease model, we and others previously demonstrated that NAMPT is over-expressed during BRAFi resistance and patient relapse/progression, becoming a driver of targeted-therapy resistance [8–11].